Tuesday, November 12, 2024

 The New US FDA Predetermined Change Control Plans (PCCPs)

The US FDA is proposing a new addition to 510(k)s and PMA submissions:  Predetermined Change Control Plans (PCCPs) for devices requiring premarket approval (PMA) or premarket notification (510(k)).  A PCCP is the documentation describing what modifications will be made to a device and how the modifications will be assessed.

A recently published draft guidance, “Predetermined Change Control Plans for Medical Devices”, Draft Guidance for Industry and FDA Staff, for comment only, issued on August 22, 2024, provides FDA’s current thinking on the information to include in a PCCP.  It is also soliciting comments from stakeholders as to the proposals it discusses.  This draft guidance recommends that a PCCP describe the planned device modifications, the associated methodology to develop, validate, and implement those modifications, and an assessment of their impact.

FDA reviews the PCCP as part of a marketing submission for a device to ensure the continued safety and effectiveness of the device, without necessitating additional marketing submissions for implementing each modification described in the PCCP.  By including a PCCP in a marketing submission for a device, manufacturers can prospectively specify and seek premarket clearance / approval for intended future modifications to a device without needing to submit additional marketing submissions or obtain further FDA authorization before implementing such modifications – provided the changes are consistent with the PCCP that has been submitted and FDA-reviewed / cleared / approved.

Obviously this is a provision where future changes / models / improvements are basically known at the time of the original 510(k) or PMA submission.  For changes made to address unforeseen issues at the time of initial submission, the two guidance documents of changes to devices needing a new submission would apply instead.  

-- jel@jelincoln.com




Wednesday, September 18, 2024


US FDA and Device AI/ML


The US FDA has announced steps toward a new regulatory framework to promote the

development of medical devices that use advanced artificial intelligence / machine

learning algorithms - AI algorithms that can learn from and act on data. They have

already authorized some devices having AI capabilities. Their AI Good Machine

Learning Practice lists 10 “guiding principles” for ML/AI¹ to apply FDA’s current

authorities in new ways to keep up with the rapid pace of innovation and still ensure

device safety and performance.

The Agency is looking beyond elemental “locked” algorithm AI devices – devices that

don’t continually adapt or learn - to “true” AI - machine learning algorithms that

continually evolve, often called “adaptive” or “continuously learning” algorithms, that

learn through real-world use. The FDA is exploring a framework to allow modifications

to algorithms to be made from real-world learning and adaptation, while still ensuring

safety and effectiveness of the software required for premarket review. They include the

algorithm’s performance, the added concerns for AI / ML software verification and

validation, the manufacturer’s plan for modifications, and the ability of the manufacturer

to manage and control risks of the modifications, including the software’s

"predetermined change control plan".


¹ https://www.fda.gov/medical-devices/software-medical-device-samd/good-machine-

learning-practice-medical-device-development-guiding-principles

-- jel@jelincoln.com 

Monday, September 16, 2024

 Major FDA Changes – The Final Rule on LDTs (Lab Developed Tests):  Many companies who sell home test kits for STDs, drug abuse tests and similar OTC, e.g., on Amazon, CVS, Walgreens, etc., have relied heavily on the FDA’s tacit neglect under FDA’s “selective enforcement” of LDTs and their definition and legal requirements.  This now has changed radically with the issuance of the FDA’s Final Rule in the Federal Register (US law) on LDTs, on July 5, 2023¹.

 In their Final Rule, the FDA has brought LDT’s back to their original intent, i.e., a limited category of tests, manufactured / assembled by CLIA (Clinical Laboratory Improvement Amendments of 1988) labs, for which no viable alternative in IVT’s / other medical devices exist and for which “targeted selective enforcement” would be employed. All other “LDT” devices will be treated by the FDA as medical devices / IVDs. There will be a 5-stage 4-year phase-out² to full compliance. The phase-out dates start with the publication date of May 6, 2024. This Final Rule will pose major problems for current suppliers of so-called LDTs to clinicians, Amazon, CVS, Walgrens, etc.

 All LTV’s are medical devices, and now will be regulated as such, per the Final Rule, including company (commercial manufacturer / lab) registration, device listings, premarket review (510(k), PMA, IDE, De Novo) where applicable (Class II and III), adherence to the CGMPs for devices (21 CFR 820 / ISO 13485), FDA inspections, US FDA MDR reporting  (Medical Device Reporting), Labeling requirements, et al.  

 ¹Final Rule, LDTs:  https://www.federalregister.gov/documents/2024/05/06/2024-08935/medical-devices-laboratory-developed-tests

 ²Phase-out Schedule:  https://www.fda.gov/medical-devices/laboratory-developed-tests-faqs/phaseout-policy-and-enforcement-discretion-policies-laboratory-developed-tests-faqs

-- jel@jelincoln.com


Sunday, May 12, 2024

 APQP - Advanced Product Quality Planning


APQP had its start with the auto industry (1980s).  Some of its basic principles are taken from ISO 9001, QS 9000, and IATF 16949 (International Automotive Task Force).  Its goal is to provide a guide to assist sharing of development and other key data between suppliers and automotive companies to meet "customer" requirements and support continuous improvement .  Focus is on design, specification compliance, production processes, QC, process capability, product testing  and training.  Obviously compatible with ISO 13485 for the US and EU / Asia.  APQP tools include the 8Ds, SPC, FMEA, 6 Sigma, GR&R+, V&V, design reviews, and similar (see also the US FDA Production and Process Control for devices, pharma, combination devices).  

Some are promoting key elements of APAP for the medical device industry. As you can see by the above, the key elements are already in the US QSR and new QMSR, as well as Europe's MDR / ISO 13485 (and now with the US as well).

jel@jelincoln.com

Wednesday, March 27, 2024

 eSTAR 510(k) Submission Elements / Templates:


   Submission Type
   Cover Letter / Letters of Reference 
   Applicant Information 
   Pre-Submission Correspondence and Previous Regulator Interaction 
   Consensus Standards
   Device Description
   Proposed Indications for Use (Form FDA 3881)
   Classification
   Predicates and Substantial Equivalence (includes matrix and discussion)
   Design / Special Controls, Health Risks, and Mitigations (special 
    510(k) only)
   Labeling (labels, IFUs) 
   Reprocessing 
   Sterility
   Shelf Life
   Biocompatibility
   Software / Firmware
   Cybersecurity / Interoperability
   EMC, Electrical, Mechanical, Wireless and Thermal Safety
   Performance Testing
   References (literature, if any)
   Administrative Documentation, e.g., executive summary (recommended), a Truthful and Accuracy   
   Statement, and a 510(k) Summary or Statement) 
   Amendment / Additional Information response (responses to Additional Information requests).\

  Note:  The US 510(k), IDE, De Novo, PMA submission is similar to the EU Technical Document  
  File, in basic content and purpose (proof of meeting regulatory marketing requirements).  

   -- jel@jelincoln.com 








Tuesday, February 6, 2024

 The New QMSR, the CGMPs for Devices

Consists of:

  • ISO 13485:2016, included in its entirety by reference in  revised 21 CFR 820;
  • ISO 9000:2015, clause 3 (definitions), included by by reference in 820;
  • "Read only" copies of both the above are available on the web - addresses provided in the QMSR;
  • Most of previous 21 CFR 820, including all of C-O subparts, have been removed and reserved;
  • New Subparts A and B comprise the rest of the QMSR, 21 CFR 820.
  • The FDA has stated they are not changing the scope of the QSR in the new QMSR.  So read ISO 13485 as if it includes all of the old QSR in general.  Areas of special emphasis are in the new QMSR / 820 subparts (to address the pertinent requirements of the US' FD&C Act not fully addressed in ISO 13485). 
  • Basic changes are in some changes to definitions, the elimination of FDA's past policy of not reviewing a company's internal audits, quality reviews, vendor audits, increased emphasis on labeling beyond ISO 13485.  
  • ISO 13485's emphasis on risk management to be ISO 14971's definition: to patient, to user/clinician, to use environment plus compliance risk.
  • Corresponding changes to QSIT and applicable guidance documents and 21 CFR 4, Combination Products, will be made.
  • Until a company completes the change, they will be required to follow and be inspected to the the old QSR. 
  • FDA has settled on a two year transition period, until 02/02/2026.
The change will require a rewrite of a company's Quality Manual and QMS SOPs, primarily in terminology and reference citations, not in the specific functions addressed. Training in the same will also be necessary.

      -- https://www.fda.gov/medical-devices/quality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp/quality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked

      -- jel@jelincoln.com

Eliminated a typo on Subpart B and added reference to the US' Food, Drug and Cosmetic (FD&C Act). - JEL 05/01/2024
To clarify, the FDA has stated that it will not inspect to the new QMSR until the two year implementation period has ended, Feb 02, 2026. - JEL 10/08/2024  
     

Wednesday, January 31, 2024

I just received an FDA announcement that the new QMSR (21 CFR 820) which incorporates ISO 13485 by reference, is now, as of February 02, 2024 (when published in the Federal Register), in effect, replacing the previous version of 21 CFR 820, the QSR.  Companies have two years to complete the changeover.  Until changed, a company is responsible to be in compliance to the older QSR.  The Quality Manual, SOPs, terminology, a Device Risk Management File and QMS addressing patient safety / risk needs to be in place. This has always been required but now it's emphasized.

"FDA Issues Quality Management System Regulation: Final Rule Amending the Quality System Regulation

To ensure medical devices on the market are safe, effective, and of good quality, the U.S. Food and Drug Administration (FDA) issued the Quality Management System Regulation (QMSR) Final Rule.

The QMSR rule emphasizes risk management activities and risk-based decision making and aims to reduce regulatory burdens on device manufacturers and importers by harmonizing domestic and international requirements.

The rule amends the current good manufacturing practice requirements of the Quality System regulation in 21 CFR 820.

“This final rule is the latest action taken by the FDA to promote global harmonization in device regulation to help assure that patients and providers have timely and continued access to safe, effective, and high-quality medical devices both at home and abroad,” said Jeff Shuren, M.D., J.D., director of the FDA's Center for Devices and Radiological Health. “By harmonizing key areas of a medical device manufacturer’s quality management system with the international standard, the FDA is streamlining actions device manufacturers must take to meet requirements by multiple regulatory authorities.”

Device manufacturers and importers will have two years to modify their Quality Systems to meet the requirements of the QMSR rule by February 2, 2026. Until then, manufacturers are required to comply with the existing Quality System regulation."

  -- https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp?utm_medium=email&utm_source=govdelivery

-- jel@jelincoln.com